Hepatitis C virus, steatosis and lipid abnormalities: Clinical and pathogenic data

Liver International

Volumn 29, Issue SUPPL. 2, 2009, Pages 26-37

  Negro, Francesco ^a   Sanyal, Arun J ^b  

^a UNIVERSITY HOSPITAL   (Switzerland)

^b VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Hepatic fibrosis; Hepatitis C virus; Lipids; Steatosis

Indexed keywords

ALPHA INTERFERON; APOLIPOPROTEIN B; CELL DNA; CORE PROTEIN; FATTY ACID SYNTHASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; PEGINTERFERON ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; REACTIVE OXYGEN METABOLITE; RIBAVIRIN; STEROL REGULATORY ELEMENT BINDING PROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ANTIVIRAL THERAPY; CALCIUM TRANSPORT; CHOLESTEROL BLOOD LEVEL; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DNA DAMAGE; FATTY LIVER; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSCRIPTION; GENOTYPE; HEPATITIS C; HUMAN; HYPOBETALIPOPROTEINEMIA; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPID PEROXIDATION; LIPID STORAGE; LIVER FIBROSIS; LIVER MITOCHONDRION; MITOCHONDRIAL RESPIRATION; MONOTHERAPY; NONALCOHOLIC FATTY LIVER; REVIEW; RISK FACTOR; TREATMENT RESPONSE; VIRUS LOAD;

FATTY LIVER; GENE EXPRESSION REGULATION; HEPACIVIRUS; HEPATITIS C; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; REACTIVE OXYGEN SPECIES;

EID: 59349094958     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01950.x     Document Type: Review

References (46)

1. Ramesh S, Sanyal AJ. Hepatitis C and nonalcoholic fatty liver disease. Semin Liver Dis 2004; 24: 399-413.
2. Leandro G, Mangia A HCV Meta-Analysis (on) Individual Patients' Data Study Group et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: A meta-analysis of individual patient data. Gastroenterology 2006; 130: 1636-42.
3. Younossi ZM, Mccullough AJ, Ong JP, et al. Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol 2004; 38: 705-9.
4. Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: Relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002; 36: 729-36.
5. Szanto P, Grigorescu M, Dumitru I, Serban A. Steatosis in hepatitis C virus infection. Response to anti-viral therapy. J Gastrointestin Liver Dis 2006; 15: 117-24.
6. Koike K, Moriya K. Metabolic aspects of hepatitis C viral infection: steatohepatitis resembling but distinct from NASH. J Gastroenterol 2005; 40: 329-36.
7. Romero-Gómez M. Hepatitis C and insulin resistance: Steatosis, fibrosis and non-response. Rev Esp Enferm Dig 2006; 98: 605-15.
8. Yki-Järvinen H. Fat in the liver and insulin resistance. Ann Med 2005; 37: 347-56.
9. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 1649-57.
10. Scheen AJ, Luyckx FH. Obesity and liver disease. Best Pract Res Clin Endocrinol Metab 2002; 16: 703-16.
11. Bajaj M, Suraamornkul S, Pratipanawatr T, et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 2003; 52: 1364-70.
12. Mayerson AB, Hundal RS, Dufour S, et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002; 51: 797-802.
13. Tiikkainen M, Häkkinen AM, Korsheninnikova E, et al. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004; 53: 2169-76.
14. Fartoux L, Poujol-Robert A, Guéchot J, et al. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005; 54: 1003-8.
15. Stiles B, Wang Y, Stahl A, et al. Liver-specific deletion of negative regulator pten results in fatty liver and insulin hypersensitivity [corrected]. Proc Natl Acad Sci USA 2004; 101: 2082-7. Erratum in: Proc Natl Acad Sci USA 2004;101: 5180.
16. Schonfeld G, Yue P, Lin X, Chen Z. Fatty liver and insulin resistance: not always linked. Trans Am Clin Climatol Assoc 2008; 119: 217-24.
17. Puri P, Baillie RA, Wiest MM, et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007; 46: 1081-90.
18. Rubbia-Brandt L, Quadri R, Abid K, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000; 33: 106-15.
19. Abid K, Pazienza V, de Gottardi A, et al. An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation. J Hepatol 2005; 42: 744-51.
20. Siagris D, Christofidou M, Theocharis GJ, et al. Serum lipid pattern in chronic hepatitis C: Histological and virological correlations. J Viral Hepat 2006; 13: 56-61.
21. Wisniewska-Ligier M, Wozniakowska-Gesicka T, Kups J, Sulat-Syncerek D. Lipid metabolism in children with chronic hepatitis C, a preliminary report. Hepatogastroenterology 2006; 53: 887-91.
22. Hofer H, Bankl HC, Wrba F, et al. Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a. Am J Gastroenterol 2002; 97: 2880-5.
23. Economou M, Milionis H, Filis S, et al. Baseline cholesterol is associated with the response to antiviral therapy in chronic hepatitis C. J Gastroenterol Hepatol 2008; 23: 586-91.
24. Serfaty L, Andreani T, Giral P, et al. Hepatitis C virus induced hypobetalipoproteinemia: A possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001; 34: 428-34.
25. Su AI, Pezacki JP, Wodicka L, et al. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci USA 2002; 99: 15669-74.
26. Jackel-Cram C, Babiuk LA, Liu Q. Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: Genotype-3a core has a stronger effect than genotype-1b core. J Hepatol 2007; 46: 999-1008.
27. Yamaguchi A, Tazuma S, Nishioka T, et al. Hepatitis C virus core protein modulates fatty acid metabolism and thereby causes lipid accumulation in the liver. Dig Dis Sci 2005; 50: 1361-71.
28. Dreyer C, Krey G, Keller H, et al. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 1992; 68: 879-87.
29. Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: The second decade. Cell 1995; 83: 835-9.
30. Dharancy S, Malapel M, Perlemuter G, et al. Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology 2005; 128: 334-42.
31. Hsu MH, Savas U, Griffin KJ, Johnson EF. Identification of peroxisome proliferator-responsive human genes by elevated expression of the peroxisome proliferator-activated receptor alpha in HepG2 cells. J Biol Chem 2001; 276: 27950-8.
32. Tanaka N, Moriya K, Kiyosawa K, et al. PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. J Clin Invest 2008; 118: 683-94.
33. Waris G, Felmlee DJ, Negro F, Siddiqui A. Hepatitis C virus induces proteolytic cleavage of sterol regulatory element binding proteins and stimulates their phosphorylation via oxidative stress. J Virol 2007; 81: 8122-30.
34. Brown MS, Goldstein JL. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc Natl Acad Sci USA 1999; 96: 11041-8.
35. Horton JD, Goldstein JL, Brown MS. SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 1125-31.
36. Moriishi K, Mochizuki R, Moriya K, et al. Critical role of PA28gamma in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis. Proc Natl Acad Sci USA 2007; 104: 1661-6.
37. Perlemuter G, Sabile A, Letteron P, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: A model of viral-related steatosis. FASEB J 2002; 16: 185-94.
38. Mirandola S, Realdon S, Iqbal J, et al. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology 2006; 130: 1661-9.
39. Wang T, Weinman SA. Causes and consequences of mitochondrial reactive oxygen species generation in hepatitis C. J Gastroenterol Hepatol 2006; 21(Suppl. 3):S34-7.
40. Okuda M, Li K, Beard MR, et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002; 122: 366-75.
41. Korenaga M, Wang T, Li Y, et al. Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J Biol Chem 2005; 280: 37481-8.
42. Li Y, Boehning DF, Qian T, Popov VL, Weinman SA. Hepatitis C virus core protein increases mitochondrial ROS production by stimulation of Ca2+ uniporter activity. FASEB J 2007; 21: 2474-85.
43. Machida K, Cheng KT, Lai CK, et al. Hepatitis C virus triggers mitochondrial permeability transition with production of reactive oxygen species, leading to DNA damage and STAT3 activation. J Virol 2006; 80: 7199-207.
44. Jhaveri R, Mchutchison J, Patel K, Qiang G, Diehl AM. Specific polymorphisms in hepatitis C virus genotype 3 core protein associated with intracellular lipid accumulation. J Infect Dis 2008; 197: 283-91.
45. Hourioux C, Patient R, Morin A, et al. The genotype 3-specific hepatitis C virus core protein residue phenylalanine 164 increases steatosis in an in vitro cellular model. Gut 2007; 56: 1302-8.
46. Piodi A, Chouteau P, Lerat H, Hézode C, Pawlotsky JM. Morphological changes in intracellular lipid droplets induced by different hepatitis C virus genotype core sequences and relationship with steatosis. Hepatology 2008; 48: 16-27.